Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1913-1920

  Gabizon, Alberto A ^a,c   Tzemach, Dinah ^a   Horowitz, Aviva T ^b   Shmeeda, Hilary ^a   Yeh, Jerry ^d   Zalipsky, Samuel ^d  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CHOLESTEROL; DOXORUBICIN; LIPOSOME; MITOMYCIN C; PHOSPHATIDYLCHOLINE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CIRCULATION TIME; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; HYDROGENATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; INHIBITORY CONCENTRATION 50; LIPOSOMES; MICE; MICE, INBRED BALB C; MITOMYCINS; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645652328     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1547     Document Type: Article

References (48)

1. Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976;3:121-39.
2. Sartorelli AC. The role of mitomycin antibiotics in the chemotherapy of solid tumors. Biochem Pharmacol 1986;35:67-9.
3. Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 1997;76:73-87.
4. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 1994;6:461-75.
5. Sartorelli AC, Hodnick WF, Belcourt MF, et al. Mitomycin C: a prototype bioreductive agent. Oncol Res 1994;6:501-8.
6. Hoey BM, Butler J, Swallow AJ. Reductive activation of mitomycin C. Biochemistry 1988;27:2608-14.
7. Pan SS, Andrews PA, Glover CJ, Bachur NR. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 1984;259:959-66.
8. Lambert PA, Kang Y, Greaves B, Perry RR. The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines. J Surg Res 1998;80:177-81.
9. Ekins S, Kim RB, Leake BF, et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 2002;61:964-73.
10. Ekins S, Kim RB, Leake BF, et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 2002;61:974-81.
11. Monden N, Abe S, Hishikawa Y, et al. The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy. Int J Surg Investig 1999;1:3-10.
12. Gontero P, Sargent JM, Hopster DJ, et al. Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P-glycoprotein and apoptotic factors. Anticancer Res 2002;22:4073-80.
13. Gabizon AA, Indap M, Horowitz AT. Therapeutic potential of mitomycin A: activity against multidrug resistant tumors. Proc Am Soc Clin Oncol (ASCO 37th annual meeting) 2001. Abstract 2146. Available from: www.asco.org.
14. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1990;1:5-13.
15. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-4.
16. Gabizon AA. Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. J Drug Target 2002;10:535-8.
17. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36.
18. Mori A, Kennel SJ, van Borssum Waalkes M, Scherphof GL, Huang L. Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung metastasis model. Cancer Chemother Pharmacol 1995;35:447-56.
19. Asai T, Kurohane K, Shuto S, et al. Antitumor activity of 5′-O-dipalmitoylphosphatidyl 2′-C-cyano-2′-deoxy-1-β-D- arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization. Biol Pharm Bull 1998;21:766-71.
20. Zalipsky S, Kiwan R, Qazen M, et al. New liposomal prodrug of mitomycin C. Proc Int Symp Control Rel Bioact Mater 2001;28:437-8.
21. Zalipsky S, Gabizon AA. Conjugate having a cleavable linkage for use in a liposome. United States Patent US 6,365,179 B1. 2002.
22. Senter PD, Pearce WE, Greenfield RS. Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides. J Org Chem 1990;55:2975-8.
23. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multi-drug-resistance efflux pump. Clin Cancer Res 2000;6:1949-57.
24. Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracydines. J Drug Target 1996;3:391-8.
25. Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992;1109:203-9.
26. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992;52:6774-81.
27. Gabizon AA, Pappo O, Goren D, Chemla M, Tzemach D, Horowitz AT. Preclinical studies with doxorubicin encapsulated in polyethyleneglycol-coated liposomes. J Liposome Res 1993;3:517-28.
28. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002;10:539-48.
29. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54 Suppl 4:15-21.
30. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004;31 Suppl 13:5-15.
31. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001;7:223-5.
32. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 1995;16:285-94.
33. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60.
34. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003;42:1089-105.
35. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000;29:312-22.
36. Söderberg A, Sahaf B, Rosén A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic: presence in human plasma. Cancer Res 2000;60:2281-9.
37. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997;24:337-44.
38. Zalipsky S, Qazen M, Walker JA II, Mullah IM, Quinn YP, Huang SK. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem 1999;10:703-7.
39. Jocelyn PC. Biochemistry of the SH group: the occurrence, chemical properties, metabolism and biological function of thiols and disulphides. London: Academic Press: 1972.
40. Jørgensen K, Davidsen J, Mouritsen OG. Biophysical mechanisms of phospholipase A(2) activation and their use in liposome-based drug delivery. FEBS Lett 2002;531:23-7.
41. Kojima T, Hashida M, Muranishi S, Sezaki H. Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C. J Pharm Pharmacol 1980;32:30-4.
42. Takakura Y, Takagi A, Hashida M, Sezaki H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm Res 1987;4:293-300.
43. Song Y, Onishi H, Nagai T. Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate. Biol Pharm Bull 1993;16:48-54.
44. Seymour LW, Soyez H, De Marre A, Shoaibi MA, Schacht EH. Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation. Anticancer Drug Des 1996;11:351-65.
45. Tokunaga Y, Iwasa T, Fujisaki J, Sawai S, Kagayama A. Liposomal sustained-release delivery systems for intravenous injection. I. Physicochemical and biological properties of newly synthesized lipophilic derivatives of mitomycin C. Chem Pharm Bull (Tokyo) 1988;36:3060-9.
46. Sasaki H, Kakutani T, Hashida M, Sezaki H. Characterization of liposomes and an emulsion containing mitomycin C or lipophilic mitomycin C prodrugs. J Pharm Sci 1986;75:1166-70.
47. Peer D, Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 2004;108:780-9.
48. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-36.